27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Analyst Stock Ratings Upgrades

Analyst upgrades are typically bullish for a stock. When there is a stock upgrade, the analysts who rate the stock feel better about the company's future and typically either recommend someone holds or buys the stock. Updated 05/06/2024

No data available to display
date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert

Recent Analyst Stock Rating Upgrade News

UBS Upgrades Vale to Buy, Raises Price Target to $15
UBS analyst Myles Allsop upgrades Vale (NYSE:VALE) from Neutral to Buy and raises the price target from $13 to $15.
Citigroup Upgrades Gap to Buy, Raises Price Target to $28
Citigroup analyst Paul Lejuez upgrades Gap (NYSE:GPS) from Neutral to Buy and raises the price target from $21 to $28.
Barclays Upgrades Omnicom Group to Overweight, Raises Price Target to $110
Barclays analyst Julien Roch upgrades Omnicom Group (NYSE:OMC) from Equal-Weight to Overweight and raises the price target from $100 to $110.
Compass Point Upgrades Sunstone Hotel Invts to Neutral, Raises Price Target to $12
Compass Point analyst Floris Van Dijkum upgrades Sunstone Hotel Invts (NYSE:SHO) from Sell to Neutral and raises the price target from $10 to $12.
Citigroup Upgrades Target to Buy
Citigroup analyst Paul Lejuez upgrades Target (NYSE:TGT) from Neutral to Buy.
Piper Sandler Upgrades Territorial Bancorp to Neutral, Raises Price Target to $8.5
Piper Sandler analyst Andrew Liesch upgrades Territorial Bancorp (NASDAQ:TBNK) from Underweight to Neutral and raises the price target from $8 to $8.5.
Wolfe Research Upgrades Insulet to Outperform, Announces $200 Price Target
Wolfe Research analyst Mike Polark upgrades Insulet (NASDAQ:PODD) from Peer Perform to Outperform and announces $200 price target.
Piper Sandler Upgrades Design Therapeutics to Overweight, Raises Price Target to $12
Piper Sandler analyst Yasmeen Rahimi upgrades Design Therapeutics (NASDAQ:DSGN) from Neutral to Overweight and raises the price target from $6 to $12.
Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97
Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and raises the price target from $50 to $97.
What's Going On With Micron Tech Stock On Monday?
Analyst upgrades Micron Technology Inc (MU) from Neutral to Outperform, raises price target to $150. Remains bullish on US semiconductor sector.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free